Objective:Study the clinical effect of atorvastatin combined with clopidogrel on patients with progressive cerebral infarction of intracranial aortic stenosis.Methods: Chose eighty-eight patients with progressive cere...Objective:Study the clinical effect of atorvastatin combined with clopidogrel on patients with progressive cerebral infarction of intracranial aortic stenosis.Methods: Chose eighty-eight patients with progressive cerebral infarction in our hospital from June 2014 to October 2015. They were randomly divided into study group and study group, 44 cases in each group. The patients in the control group were treated with oral clopidogrel. On the basis of this, the patients in the study group were treated with atorvastatin;all patients were treated for 4 weeks. Compared the total effective rate, adverse reaction rate, coagulation function index and blood lipid level between the two groups, and compared the NIHSS score and daily life ability (ADL) score between the two groups before and after treatment.Results: The total effective rate (90.90%) was significantly higher in the study group than in the control group (72.73%). After treatment, the NIHSS score of the study group was significantly lower than that of the control group. The levels of LDL-C, TG and TC in the study group were significantly lower than those in the control group, and HDL-C was significantly higher than that in the control group. There was no significant difference between the two groups.Conclusion: Clopidogrel combined with atorvastatin has a significant effect on the patients with intracranial large artery stenosis and improve the neurological function and quality of life. It is safe and reliable. It is worthy to be popularized.展开更多
目的比较阿加曲班联合阿司匹林与替罗非班治疗进展性脑梗死的疗效和安全性。方法收集2021年6月—2023年10月在南方医院增城院区住院诊治的进展性脑梗死患者101例,将收集的病例患者分为两组,A组(n=64)应用阿加曲班+阿司匹林治疗,B组(n=37...目的比较阿加曲班联合阿司匹林与替罗非班治疗进展性脑梗死的疗效和安全性。方法收集2021年6月—2023年10月在南方医院增城院区住院诊治的进展性脑梗死患者101例,将收集的病例患者分为两组,A组(n=64)应用阿加曲班+阿司匹林治疗,B组(n=37)应用替罗非班治疗,记录两组患者治疗前后美国国立卫生研究院脑卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分、改良Rankin量表(modified Rankin Scale,mRS)评分及巴氏指数评定量表(Barthel Index,BI)来评估患者在不同时间段的治疗效果,同时记录治疗过程中各种出血并发症来评估用药安全性。结果在治疗大动脉粥样硬化型进展性脑梗死患者中,A组治疗后48 h、7 d、出院时NIHSS、30 d、90 d mRS较B组均有下降(P<0.05),治疗后30 d、90 d BI较B组升高(P<0.05);在治疗小血管闭塞型进展性脑梗死患者中,两组用药差异无统计学意义(P>0.05);在治疗后循环进展性脑梗死患者中,A组出院时NHISS评分低于B组(P<0.05);两组治疗后30 d、90 d mRS评分均有下降(P>0.05),治疗后30 d BI指数、90 d BI指数均有上升(P>0.05);两组用药治疗前循环进展性脑梗死差异无统计学意义(P>0.05);两组用药治疗过程中均无严重不良反应(P>0.05)。结论阿加曲班联合阿司匹林治疗大动脉粥样硬化型进展性脑梗死较替罗非班组效果好,两组治疗小血管闭塞性进展性脑梗死疗效相当;阿加曲班联合阿司匹林治疗后循环进展性脑梗死早期效果较替罗非班可能更好,两组治疗前循环进展性脑梗死效果相当;两组用药安全性相当,未发生严重的出血不良事件。展开更多
文摘Objective:Study the clinical effect of atorvastatin combined with clopidogrel on patients with progressive cerebral infarction of intracranial aortic stenosis.Methods: Chose eighty-eight patients with progressive cerebral infarction in our hospital from June 2014 to October 2015. They were randomly divided into study group and study group, 44 cases in each group. The patients in the control group were treated with oral clopidogrel. On the basis of this, the patients in the study group were treated with atorvastatin;all patients were treated for 4 weeks. Compared the total effective rate, adverse reaction rate, coagulation function index and blood lipid level between the two groups, and compared the NIHSS score and daily life ability (ADL) score between the two groups before and after treatment.Results: The total effective rate (90.90%) was significantly higher in the study group than in the control group (72.73%). After treatment, the NIHSS score of the study group was significantly lower than that of the control group. The levels of LDL-C, TG and TC in the study group were significantly lower than those in the control group, and HDL-C was significantly higher than that in the control group. There was no significant difference between the two groups.Conclusion: Clopidogrel combined with atorvastatin has a significant effect on the patients with intracranial large artery stenosis and improve the neurological function and quality of life. It is safe and reliable. It is worthy to be popularized.
文摘目的比较阿加曲班联合阿司匹林与替罗非班治疗进展性脑梗死的疗效和安全性。方法收集2021年6月—2023年10月在南方医院增城院区住院诊治的进展性脑梗死患者101例,将收集的病例患者分为两组,A组(n=64)应用阿加曲班+阿司匹林治疗,B组(n=37)应用替罗非班治疗,记录两组患者治疗前后美国国立卫生研究院脑卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分、改良Rankin量表(modified Rankin Scale,mRS)评分及巴氏指数评定量表(Barthel Index,BI)来评估患者在不同时间段的治疗效果,同时记录治疗过程中各种出血并发症来评估用药安全性。结果在治疗大动脉粥样硬化型进展性脑梗死患者中,A组治疗后48 h、7 d、出院时NIHSS、30 d、90 d mRS较B组均有下降(P<0.05),治疗后30 d、90 d BI较B组升高(P<0.05);在治疗小血管闭塞型进展性脑梗死患者中,两组用药差异无统计学意义(P>0.05);在治疗后循环进展性脑梗死患者中,A组出院时NHISS评分低于B组(P<0.05);两组治疗后30 d、90 d mRS评分均有下降(P>0.05),治疗后30 d BI指数、90 d BI指数均有上升(P>0.05);两组用药治疗前循环进展性脑梗死差异无统计学意义(P>0.05);两组用药治疗过程中均无严重不良反应(P>0.05)。结论阿加曲班联合阿司匹林治疗大动脉粥样硬化型进展性脑梗死较替罗非班组效果好,两组治疗小血管闭塞性进展性脑梗死疗效相当;阿加曲班联合阿司匹林治疗后循环进展性脑梗死早期效果较替罗非班可能更好,两组治疗前循环进展性脑梗死效果相当;两组用药安全性相当,未发生严重的出血不良事件。
